Hypertrophic Scars and Keloids (CPB 0389, reviewed 2026-05-28)
Summary
Aetna Clinical Policy Bulletin 0389 sets the coverage rules for treating hypertrophic scars and keloids. It considers intralesional 5-fluorouracil, cryotherapy, or intralesional corticosteroids medically necessary for keloids when the medical necessity criteria for keloid removal are met, and fractional ablative laser for burn, traumatic, and post-surgical scars when there is documented significant functional impairment (limited movement) and conventional treatments such as hypoallergenic paper tape or silicone gel/sheeting have been tried and failed. The policy lists many other interventions as experimental, investigational, or unproven for these scars because their effectiveness has not been established, including silicone products, intense pulsed light, bevacizumab, intralesional botulinum toxin type A, and dermal substitutes.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.